Drug interactions between chemotherapeutic regimens and antiepileptics.
Kevin Yi-Lwern Yap, Wai Keung Chui, Alexandre Chan
https://pubmed.ncbi.nlm.nih.gov/18803983/Actively Recruiting
Led by Tata Memorial Centre · Updated on 2026-02-13
604
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating the optimal duration of levetiracetam treatment in patients with primary brain tumors who have experienced seizures. This phase 3 randomized controlled trial aims to compare a shorter course of levetiracetam with the current standard longer course. The goal is to determine whether stopping levetiracetam earlier will not lead to an increased risk of seizure episodes, while considering the side effects such as headache, drowsiness, muscle coordination loss, and psychological challenges commonly associated with this medication. Participants will be randomized into two groups the standard arm, where patients continue levetiracetam at the same dose typically 1000-3000 mg per day in divided doses for two years, and the experimental arm, where the drug is gradually reduced by 250-500 mg each week and then stopped. Follow-up visits will occur every 3 to 6 months, with routine neuroimaging done every 6 to 12 months according to tumor type. Quality of life assessments will be performed every six months. If seizures recur, levetiracetam or additional antiepileptic medications will be administered as needed per usual care. During the study, patients will continue standard treatments for their brain tumors, including any necessary adjuvant therapies. Researchers will monitor seizure-free survival over two years from randomization as the primary outcome. Secondary outcomes include overall survival, progression-free survival, cost-benefit analysis, and quality of life measures over seven years. The study includes safety monitoring through planned interim analyses and will enroll 604 patients over seven years at two centers.
CONDITIONS
Short Versus Long-term Levetiracetam in Brain Tumors
A
Archya Dasgupta, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tata Memorial Centre
Lead Sponsor
Manipal Academy for Higher Education
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants are randomized to either continue levetiracetam at the same dose for 2 years or taper and stop levetiracetam over several weeks. Regular assessments and medication adjustments occur as per assigned arm.
Visits every 3 to 6 months for follow-up assessments
Duration - Up to 5 years after treatment
Participants are monitored for seizure recurrence, survival, quality of life, and tumor progression with visits every 3 to 6 months and neuroimaging every 6 to 12 months as part of routine clinical practice.
Follow-up visits every 3 to 6 months and neuroimaging every 6 to 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kevin Yi-Lwern Yap, Wai Keung Chui, Alexandre Chan
https://pubmed.ncbi.nlm.nih.gov/18803983/James M Chamberlain, Jaideep Kapur, Shlomo Shinnar...
https://pubmed.ncbi.nlm.nih.gov/32203691/Jerzy Hildebrand, Cristel Lecaille, Joëlle Perennes...
https://pubmed.ncbi.nlm.nih.gov/16043788/S-L Hwang, C-L Lin, K-S Lee...
https://pubmed.ncbi.nlm.nih.gov/15168227/J G Villemure, N de Tribolet
https://pubmed.ncbi.nlm.nih.gov/9007399/Marta Maschio, Loredana Dinapoli, Francesca Sperati...
https://pubmed.ncbi.nlm.nih.gov/21107994/Zi-Ran Li, Chen-Yu Wang, Xiao Zhu...
https://pubmed.ncbi.nlm.nih.gov/33447943/Roberta Roberti, Morena Rocca, Luigi Francesco Iannone...
https://pubmed.ncbi.nlm.nih.gov/35317697/Ingrid E Scheffer, Samuel Berkovic, Giuseppe Capovilla...
https://pubmed.ncbi.nlm.nih.gov/28276062/Dario J Englot, Stephen T Magill, Seunggu J Han...
https://pubmed.ncbi.nlm.nih.gov/26636386/Tata Memorial Centre
Lead Sponsor
Manipal Academy for Higher Education
Collaborating Sponsor